Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy”

Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy”Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy”, Published online: 24 April 2018; doi:10.1038/s41391-018-0038-9Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy”
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research

Related Links:

Publication date: Available online 17 February 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Yu-Chuan Lu, Ming-Chieh Kuo, Jian-Hua Hong, Fu-Shan Jaw, Chao-Yuan Huang, Jason Chia-Hsien Cheng, Hsiu-Ni KungBackground/PurposeThe inflammatory milieu has been firmly established to affect cancer progression. However, the connection between natural killer (NK) cells and prostate cancer (PCa) has not been elucidated.MethodsProspective data on NK cell activity (NKA) and NK cell subset distribution patterns were evaluated from 51 patients treated with robot-assisted laparoscopic radical prostatectomy. Whole-blood ...
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
Condition:   Prostate Cancer Intervention:   Procedure: lymph node dissection Sponsor:   Martini-Klinik am UKE GmbH Recruiting
Source: - Category: Research Source Type: clinical trials
Abstract Bladder neck stenosis (BNS) after simple prostatectomy and vesicourethral anastomosis stenosis (VUAS) after radical prostatectomy for prostate cancer are common sequelae. However, the two entities differ in their pathology, anatomy and their surgical results. VUAS has an incidence of 0.2-28%. Commonly, VUAS occurs within the first 2 years after surgery. Initial therapy should be performed endourologically: dilatation, (laser) incision or resection. After three unsuccessful treatment attempts, open reconstruction should be considered. Different surgical approaches (abdominal, perineal, abdominoperinea...
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Tags: Urologe A Source Type: research
url Klocker Heidegger Evidence has accumulated asserting the importance of cullin-RING (really interesting new gene) ubiquitin ligases (CRLs) and their regulator Cullin-associated neural-precursor-cell-expressed developmentally down-regulated 8 (NEDD8) dissociated protein 1 (Cand1) in various cancer entities. However, the role of Cand1 in prostate cancer (PCa) has not been intensively investigated so far. Thus, in the present study, we aimed to assess the relevance of Cand1 in the clinical and preclinical setting. Immunohistochemical analyses of radical prostatectomy specimens of PCa patients showed that Cand1 pr...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Nature Reviews Urology, Published online: 12 February 2020; doi:10.1038/s41585-020-0290-3No clear consensus exists for managing biochemically recurrent prostate cancer after prostatectomy. Interpretation of new data from the JCOG0401 trial warrants consideration of imaging techniques, prostate-specific antigen (PSA) levels at time of salvage radiotherapy (SRT), use of SRT ± salvage androgen deprivation therapy based on PSA levels, and the interval to biochemical failure.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research
Abstract For patients experiencing biochemical recurrence in the absence of distant metastasis, salvage radiotherapy (SRT) with or without androgen deprivation therapy (ADT) is currently the only possible curative treatment option. Prostate-specific antigen (PSA) monitoring and the selected use of SRT has some advantages when compared with adjuvant radiotherapy. The most important one is avoidance of a potential overtreatment of patients who would never have disease progression, even in the presence of high-risk pathological features. The identification of a specific PSA cut-off seems to be incorrect. In patients ...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Oncol (R Coll Radiol) Source Type: research
The aim of this study was to compare the cost-effectiveness and quality-adjusted life years (QALYs) of active monitoring (AM), radical prostatectomy (PR), and external-beam radiotherapy with neoadjuvant hormone therapy (RT) for localized prostate cancer. Microsimulations of radical prostatectomy, 3D-conformal radiotherapy, or active monitoring were performed using Medicare reimbursement schedules and clinical trial results for a target population of men aged 50–69 years with newly diagnosed localized prostate cancer (T1-T2, NX, M0) over a time horizon of 10 years. Quality-adjusted life years (QALYs) and costs were as...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Prostate Cancer;   Metastasis;   Prostatectomy Intervention:   Drug: Ferrotran® (Ferumoxtran-10) Sponsors:   Saving Patients' Lives Medical B.V.;   ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H.;   b.e.imaging GmbH;   Radboud University Recruiting
Source: - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Prostate Cancer | Prostatectomy | Urology & Nephrology | Weight Loss